Sorrento Therapeutics Inc
OTC:SRNE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Jinxin Fertility Group Ltd
HKEX:1951
|
CN |
|
Duroc AB
STO:DURC B
|
SE |
|
T
|
Tong Ren Tang Technologies Co Ltd
HKEX:1666
|
CN |
|
ESS Tech Inc
NYSE:GWH
|
US |
|
Rajesh Exports Ltd
NSE:RAJESHEXPO
|
IN |
|
Kozosushi Co Ltd
TSE:9973
|
JP |
|
J
|
JOST Werke AG
XETRA:JST
|
DE |
Sorrento Therapeutics Inc
Non-Reccuring Items
Sorrento Therapeutics Inc
Non-Reccuring Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Non-Reccuring Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sorrento Therapeutics Inc
OTC:SRNE
|
Non-Reccuring Items
-$122m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Non-Reccuring Items
-$5.9B
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-18%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Non-Reccuring Items
-$1.8B
|
CAGR 3-Years
24%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Non-Reccuring Items
-$7.1B
|
CAGR 3-Years
-144%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-61%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Non-Reccuring Items
-$512m
|
CAGR 3-Years
-59%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-72%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Non-Reccuring Items
-$297m
|
CAGR 3-Years
17%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-32%
|
|
Sorrento Therapeutics Inc
Glance View
Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. The company is headquartered in San Diego, California and currently employs 799 full-time employees. The company went IPO on 2007-01-19. The firm's segments include Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate cancer therapeutics. The Scilex segment is largely organized around its non-opioid pain management operations. Sorrento's immuno-oncology platforms include key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing antiviral therapies and vaccines against coronaviruses, including Abivertinib, COVI-AMG, COVISHIELD, COVI-MSC and COVIDROPS; and diagnostic test solutions, including COVITRACK and COVISTIX.
See Also
What is Sorrento Therapeutics Inc's Non-Reccuring Items?
Non-Reccuring Items
-122m
USD
Based on the financial report for Jun 30, 2023, Sorrento Therapeutics Inc's Non-Reccuring Items amounts to -122m USD.
What is Sorrento Therapeutics Inc's Non-Reccuring Items growth rate?
Non-Reccuring Items CAGR 3Y
-15%
Over the last year, the Non-Reccuring Items growth was -26%. The average annual Non-Reccuring Items growth rates for Sorrento Therapeutics Inc have been -15% over the past three years .
